Literature DB >> 15893046

Smoking behavior in persons with a schizophrenia-spectrum disorder: a qualitative investigation of the transtheoretical model.

Michelle L Esterberg1, Michael T Compton.   

Abstract

Smoking rates among persons with schizophrenia are up to three times the rates of the general US population, and research has shown that it is difficult to design cessation programs for people with schizophrenia that take into account their various cognitive and social deficits. More research is needed on the attitudes and priorities of people with schizophrenia in order to design and implement effective smoking cessation programs. Additionally, more research should be conducted with first-episode psychosis and chronic schizophrenia patients to investigate possible differences between these two groups. The purpose of this study, conducted in Atlanta, USA, was to use qualitative methodology to assess the Transtheoretical Model (TTM) in the context of smoking behavior in a sample of participants with schizophrenia-spectrum disorders. Data were obtained via interviews with 12 participants with either first-episode or chronic schizophrenia-spectrum disorders who smoked cigarettes. Differences between the two subsets of the sample were assessed. Results clustered into the following prevalent themes: (1) pros and cons of smoking; (2) beliefs about smoking cessation; (3) external influences on smoking and quitting; and (4) negative attitudes toward nicotine replacement therapies (NRT). Findings indicate that the majority of participants were in the precontemplation stage of quitting smoking, and that the primary advantages of smoking for this sample were relief from anxiety and negative symptoms. Important differences were found between chronic and first-episode participants in the areas of readiness-to-quit and beliefs about smoking cessation. Other findings indicate a lack of cessation programs offered to this sample, and overall negative attitudes toward NRT. Future interventions should take into account the reported pros and cons of smoking in this population, as well as other beliefs and attitudes regarding smoking behavior.

Entities:  

Mesh:

Year:  2005        PMID: 15893046     DOI: 10.1016/j.socscimed.2004.11.057

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  23 in total

1.  Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia.

Authors:  Daniel J Coletti; Mary Brunette; Majnu John; John M Kane; Anil K Malhotra; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2015-08-27       Impact factor: 9.306

2.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

3.  Chronic cigarette smoking modulates injury and short-term recovery of the medial temporal lobe in alcoholics.

Authors:  Stefan Gazdzinski; Timothy C Durazzo; Ping-Hong Yeh; Dawn Hardin; Peter Banys; Dieter J Meyerhoff
Journal:  Psychiatry Res       Date:  2008-02-28       Impact factor: 3.222

4.  Proactive outreach tobacco treatment for socioeconomically disadvantaged smokers with serious mental illness.

Authors:  Patrick J Hammett; Harry A Lando; Darin J Erickson; Rachel Widome; Brent C Taylor; David Nelson; Sandra J Japuntich; Steven S Fu
Journal:  J Behav Med       Date:  2019-07-30

5.  Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow; Gary B Kaplan; Robert M Swift; Amy B Adolfo
Journal:  Nicotine Tob Res       Date:  2008-06       Impact factor: 4.244

6.  Exploring online communication about cigarette smoking among Twitter users who self-identify as having schizophrenia.

Authors:  Yulin Hswen; John A Naslund; Pooja Chandrashekar; Robert Siegel; John S Brownstein; Jared B Hawkins
Journal:  Psychiatry Res       Date:  2017-08-02       Impact factor: 3.222

7.  Predictors of smoking cessation group treatment engagement among veterans with serious mental illness.

Authors:  Letitia E Travaglini; Lan Li; Clayton H Brown; Melanie E Bennett
Journal:  Addict Behav       Date:  2017-07-10       Impact factor: 3.913

8.  Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow
Journal:  Schizophr Res       Date:  2009-12       Impact factor: 4.939

9.  [Psychiatric comorbidities with tobacco-related disorders].

Authors:  S Mühlig; S Andreas; A Batra; K U Petersen; E Hoch; T Rüther
Journal:  Nervenarzt       Date:  2016-01       Impact factor: 1.214

10.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.